All In Biotech

Drug Trial Radar · NCT04242498

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 509 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

509

Actual

Start

Mar 2, 2020

Primary completion

Nov 9, 2021

Study completion Sep 28, 2022

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Jan 27, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)

Conditions

  • Hidradenitis Suppurativa

Interventions

  • BimekizumabDrug

    Subjects will receive bimekizumab at pre-specified time-points.

  • PlaceboOther

    Subjects will receive placebo at pre-specified time-points during the Initial Treatment Period.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Clinical Response as Measured by Hidradenitis Suppurativa Clinical Response 50 (HiSCR50) at Week 16Time frame: Week 16

Locations

91 sites in 14 countries. Site status is shown where the registry gives one.

  • Hs0004 50162

    Fountain Valley, California

  • Hs0004 50196

    Thousand Oaks, California

  • Hs0004 50199

    Miami, Florida

  • Hs0004 50152

    Orange Park, Florida

  • Hs0004 50144

    Orlando, Florida

  • Hs0004 50184

    Pembroke Pines, Florida

  • Hs0004 50193

    Sandy Springs, Georgia

  • Hs0004 50223

    Savannah, Georgia

  • Hs0004 50164

    Skokie, Illinois

  • Hs0004 50234

    Plainfield, Indiana

  • Hs0004 50178

    Clarkston, Michigan

  • Hs0004 50105

    St Louis, Missouri

  • Hs0004 50197

    Henderson, Nevada

  • Hs0004 50159

    Portsmouth, New Hampshire

  • Hs0004 50200

    Verona, New Jersey

  • Hs0004 50237

    Albuquerque, New Mexico

  • Hs0004 50211

    Durham, North Carolina

  • Hs0004 50179

    Winston-Salem, North Carolina

  • Hs0004 50145

    Columbus, Ohio

  • Hs0004 50202

    Fairborn, Ohio

  • Hs0004 50150

    Philadelphia, Pennsylvania

  • Hs0004 50236

    Greenville, South Carolina

  • Hs0004 50084

    Johns Island, South Carolina

  • Hs0004 50148

    Pflugerville, Texas

  • Hs0004 30018

    Parkville, Australia

  • Hs0004 30014

    St Leonards, Australia

  • Hs0004 30009

    Westmead, Australia

  • Hs0004 40313

    Pleven, Bulgaria

  • Hs0004 40284

    Sofia, Bulgaria

  • Hs0004 40311

    Sofia, Bulgaria

  • Hs0004 40314

    Sofia, Bulgaria

  • Hs0004 40315

    Sofia, Bulgaria

  • Hs0004 40353

    Stara Zagora, Bulgaria

  • Hs0004 50172

    Cobourg, Canada

  • Hs0004 50135

    Edmonton, Canada

  • Hs0004 50174

    London, Canada

  • Hs0004 50189

    St. John's, Canada

  • Hs0004 50134

    Waterloo, Canada

  • Hs0004 50136

    Winnipeg, Canada

  • Hs0004 40063

    Prague, Czechia

Showing 40 of 91 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.